CA
RKDA icon

Calton & Associates’s Arcadia Biosciences RKDA Stock Holding History

Calton & Associates’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-325
Closed -$3.52K – 278
2022
Q4 		$3.52K Hold
325
– – ﹤0.01% 283
2022
Q3 		$6K Hold
325
– – ﹤0.01% 213
2022
Q2 		$13K Hold
325
– – 0.01% 235
2022
Q1 		$18K Hold
325
– – 0.01% 347
2021
Q4 		$13K Hold
325
– – ﹤0.01% 364
2021
Q3 		$26K Hold
325
– – 0.01% 392
2021
Q2 		$39K Hold
325
– – 0.01% 403
2021
Q1 		$36K Hold
325
– – 0.01% 395
2020
Q4 		$33K Hold
325
– – 0.01% 380
2020
Q3 		$36K Hold
325
– – 0.01% 345
2020
Q2 		$49K Buy
+325
New +$50.5K 0.01% 327

Other funds holding RKDA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Calton & Associates's RKDA Position: Q1 2023 in Review

Calton & Associates sold out of Arcadia Biosciences (RKDA) in Q1 2023, closing a stake of 325 shares — an estimated $3.52K sold.

Calton & Associates first reported a position in RKDA in Q2 2020 and held it in 11 quarters. The position peaked at $49K in Q2 2020. 15 funds tracked by Wall St. Rank hold RKDA as of Q1 2023.

  • Calton & Associates reported no remaining Arcadia Biosciences position as of Q1 2023 after selling out during the quarter.
  • Calton & Associates sold 325 Arcadia Biosciences shares in Q1 2023, an estimated $3.52K.
  • Calton & Associates first reported a position in Arcadia Biosciences in Q2 2020 and held it in 11 quarters.
  • Calton & Associates's Arcadia Biosciences position peaked at $49K in Q2 2020.
  • 15 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2023.

Based on Calton & Associates's 13F filing for Q1 2023, filed 19 Apr 2023.